Brolucizumab (Beovu)


 CADTH recommends that Beovu be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met.
 should covered to treat patients with DME provided is a similar patient population and in way other anti–vascular endothelial growth factor (VEGF) drugs currently adult DME.
 only prescribed an ophthalmologist experience managing its cost not more than least costly anti-VEGF